Targeted Naltrexone in Asia-Pacific: What Access Evidence Shows
Targeted naltrexone has trial evidence, but local access depends first on whether standalone naltrexone is marketed and whether a clinician supports the protocol.
Trial evidence exists for targeted dosing, but there is no universal 78% success rate.
Product availability and protocol acceptance are different questions.
A registered Contrave product does not create a targeted addiction-treatment pathway.
Public funding rules may not cover every off-label dosing approach.
Provider directories and clinic marketing are not substitutes for regulator or pharmacy confirmation.
Country evidence snapshot, checked 26 July 2026
Country
Standalone product evidence
What targeted access means
Australia
TGA/PBS evidence for 50 mg oral naltrexone
A clinician may consider targeted dosing; confirm whether prescribing and PBS eligibility match the intended use
New Zealand
PHARMAC funds Naltraccord 50 mg under SA1408
A prescriber must check current Special Authority criteria and whether the proposed dosing plan fits funding and clinical practice
Singapore
Contrave SIN16411P verified; currently marketed standalone 50 mg product not verified
Do not assume targeted treatment is routinely available; ask NAMS or a clinician and pharmacy for the exact product
UAE
Active Contrave entry verified; standalone naltrexone not found in the live EDE search
DHA guidance names naltrexone clinically, but a clinician must verify a lawful supply route
What the clinical evidence says
The 2001 Heinälä trial involved 121 participants and included 12 weeks of daily medication followed by a targeted phase; it was not a “78% success” meta-analysis. A 2022 placebo-controlled trial in 120 sexual and gender minority men found benefits on binge-drinking and several secondary outcomes over 12 weeks.
Those trials justify informed discussion. They do not establish a guaranteed pharmacological-extinction timeline or prove that targeted dosing is superior for every person.
Questions to ask
Which exact standalone product and strength can be dispensed?
Is targeted dosing supported by the clinician and local label or guidelines?
Does any public or insurance funding apply to this dosing approach?
How will heavy-drinking days, adverse effects, and adherence be reviewed?
What is the plan after missed doses, unplanned drinking, opioid pain treatment, or no improvement?
